Functional interplay of Epstein-Barr virus oncoproteins in a mouse model of B cell lymphomagenesis
Author(s) -
Thomas Sommermann,
Tomoharu Yasuda,
Jonathan Ronen,
Tristan Wirtz,
Timm Weber,
Ulrike Sack,
Rebecca Caeser,
Jingwei Zhang,
Xun Li,
Van Trung Chu,
Anna Jauch,
Kristian Unger,
Daniel J. Hodson,
Altuna Akalin,
Klaus Rajewsky
Publication year - 2020
Publication title -
proceedings of the national academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 5.011
H-Index - 771
eISSN - 1091-6490
pISSN - 0027-8424
DOI - 10.1073/pnas.1921139117
Subject(s) - epstein–barr virus , biology , b cell , virus , cell , cancer research , phenocopy , virology , microbiology and biotechnology , gene , immunology , antibody , genetics , phenotype
Significance Epstein-Barr virus (EBV) efficiently transforms human B cells and causes B cell lymphomagenesis especially in immunocompromised patients. We study this process in genetically engineered mice to untangle the interplay of EBV oncogenes. We find Epstein-Barr nuclear antigen (EBNA) 3A to have both oncogenic and tumor suppressive roles. First, EBNA3A promotes B cell transformation by inhibiting LMP-driven plasma cell differentiation, a function which can be mimicked by aberrant activation of early B cell factor 1 (EBF1). Second, EBNA3A blunts Myc-driven proliferation, rendering B cell transformation dependent on Myc activation by the EBV protein EBNA2. The presented mouse model thus highlights the role of EBV oncogenes in orchestrating B cell transformation through control of B cell differentiation and Myc levels.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom